This trial is for patients with metastatic castration-resistant Prostate Cancer who are eligible for abiraterone (Zytiga) but have not yet begun this treatment.
The IPATential150 clinical trial is to compare the effectiveness, safety, and response to the addition of the investigational new drug ipatasertib to the FDA approved drug abiraterone with prednisone in patients with castration-resistant prostate cancer that has spread (metastatic).
Patients who participate in the IPATential150 trial are randomly (by chance) assigned to either a group to receive ipatasertib plus abiraterone with prednisone (a current standard of care) or to a group that will receive only abiraterone with prednisone plus placebo.
IPATential150 is a phase 3 clinical trial that will enroll approximately 1,100 patients. The trial began in 2017 and the primary analysis date is 2020.
Possible patient benefits include slowing down the progression of their prostate cancer and potentially prolonging life. Patients will also be under close medical supervision for medication side effects and detection of any possible progression of their disease.
Possible patient risks: Ipatasertib will not work any better than abiraterone in preventing disease progression.
To Learn more about the IPATential150 clinical trial and to find out if you may be eligible, please visit www.clinicaltrials.gov (Study Identifier: NCT03072238)